Literature DB >> 25773656

Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience.

Oscar Epis1, Cinzia Casu, Laura Belloli, Emanuela Schito, Davide Filippini, Marina Muscarà, Eleonora Bruschi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25773656     DOI： 10.1007/s00296-015-3243-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  5 in total

1.  Imaging in rheumatology: ultrasafe + ultrasure = ultrasound.

Authors:  Oscar Epis; Luca Giacomelli; Eleonora Bruschi
Journal:  Rheumatol Int       Date:  2012-03-24       Impact factor: 2.631

Review 2.  Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.

Authors:  Sohita Dhillon
Journal:  BioDrugs       Date:  2014-02       Impact factor: 5.807

3.  Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity.

Authors:  N van Herwaarden; S Herfkens-Hol; A van der Maas; B J F van den Bemt; R F van Vollenhoven; J W J Bijlsma; A A den Broeder
Journal:  Clin Exp Rheumatol       Date:  2014-04-28       Impact factor: 4.473

Review 4.  Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.

Authors:  Aarat M Patel; Larry W Moreland
Journal:  Drug Des Devel Ther       Date:  2010-10-01       Impact factor: 4.162

Review 5.  Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors.

Authors:  Toshio Tanaka; Yoshihiro Hishitani; Atsushi Ogata
Journal:  Biologics       Date:  2014-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.